Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants ...Middle East

Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date The amubarvimab/romlusevimab combination is commercially available in China and is...

Hence then, the article about brii biosciences announces positive data demonstrating its long acting covid 19 neutralizing antibody therapy amubarvimab romlusevimab combination retains neutralizing activity against live omicron virus ba 4 5 and ba 2 12 1 subvariants was published today ( Wednesday 27/07/2022 - 02:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants )

Also on site :

• Union boss ‘held up Communist flag alongside people singing pro-Russia chants in occupied Ukraine’
• Large house fire near Buckeye Lake kills one, critically injures second victim
• Regained momentum sets Yemen government’s eyes on Houthis in the north